前列地尔联合腺苷蛋氨酸治疗病毒性肝炎高胆红素血症疗效观察

目的观察前列地尔联合腺苷蛋氨酸治疗病毒性肝炎高胆红素血症的临床疗效及安全性。方法选取符合病毒性肝炎诊断标准、血清总胆红素（TBIL）〉171.1μmol/L的住院患者72例,随机分为治疗组与对照组,两组均用腺苷蛋氨酸治疗,治疗组加用前列地尔,疗程为4周。观察患者治疗前后症状变化及TBIL、ALT、γ-GT指标变化。结果治疗组总有效率显著优于对照组（94.12%vs 76.32%,P〈0.05）;两组患者临床表现和肝功能（TBIL、ALT、γ-GT）均较治疗前有明显改善（P〈0.05）,治疗后治疗组TBIL下降幅度与对照组比较有显著性差异（P〈0.01）,而ALT和γ-GT下降幅度与对照组比较差异无统计学意义（P〉0.05）。治疗期间两组病例均未出现不良反应。结论前列地尔联合腺苷蛋氨酸治疗病毒性肝炎高胆红素血症具有较好的疗效和安全性。

Efficiency of Alprostadil combined with S-adenosyl-L-methionine (SAMe) in treatment of viral hepatitis with hyperbilirubinemia

Objective To observe the therapeutic efficacy and safety of Alprostadil combined with S-adenosyl-L-methionine(SAMe) in treatment of viral hepatitis with hyperbilirubinemia.Methods Seventy-two cases of viral hepatitis patients with TBIL>171.1 μmol/L were randomly divided into control group and treatment group.The control group was given with SAMe alone,while the treatment group was treated with Alprostadil combined with SAMe.The patients’ symptom and serum TBIL,ALT,γ-GT were measured before treatment and at 4 weeks after treatment.Results The total effective rate of the treatment group was significantly higher than that in the control group(94.12% vs 76.32%,P<0.05).At 4 weeks after treatment,clinical manifestations and liver function(TBIL,ALT and γ-GT) significantly improved than pretreatment in both groups(P<0.05).The decline in serum TBIL level was more significant in the treatment group than that in the control group(P<0.05).But the decline in serum ALT and γ-GT levels showed no statistical difference between two groups(P>0.05).No adverse reaction was found in both groups.Conclusion Treatment of viral hepatitis with hyperbilirubinemia with Alprostadil in combination with S-adenosyl-L-methionine(SAMe) is effective and safe.